Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07083349 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

StatusTerminated
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Not Yet Recruiting → Terminated Sponsor's reason: poor accrual Show 6 more changesShow less
    • Phase changed: not applicable → Early Phase 1
    • Start date changed from estimate of Aug 1, 2025 to Dec 1, 2025
    • Final enrollment: 4 participants (planned 9)
    • Primary completion date changed from estimate of Sep 1, 2027 to Apr 1, 2026
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Secondary endpoints revised (4)v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China.
Trial Details
NCT Number NCT07083349
Lead Sponsor Base Therapeutics (Shanghai) Co., Ltd.
Collaborators: The First Affiliated Hospital of Anhui Medical University
Conditions
(from sponsor)		 Refractory Systemic Lupus Erythematosus
Related terms Lupus Erythematosus, Systemic
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov